X0306 4 2019-07-31 0 0001609550 Inspire Medical Systems, Inc. INSP 0001737127 Ban Randy C/O INSPIRE MEDICAL SYSTEMS, INC. 5500 WAYZATA BLVD., SUITE 1600 GOLDEN VALLEY MN 55416 0 1 0 0 Chief Commercial Officer Common Stock 2020-03-04 4 M 0 10000 1.14 A 10000 D Common Stock 2020-03-04 4 S 0 1801 84.33 D 8199 D Common Stock 2020-03-04 4 S 0 1673 85.19 D 6526 D Common Stock 2020-03-04 4 S 0 1613 86.38 D 4913 D Common Stock 2020-03-04 4 S 0 1730 87.40 D 3183 D Common Stock 2020-03-04 4 S 0 3044 88.09 D 139 D Common Stock 2020-03-04 4 S 0 139 89.10 D 0 D Common Stock 167 I By son Common Stock 166 I By daughter Stock Option (Right to Buy) 67.63 2019-07-31 4 A 0 25000 0 A 2029-07-31 Common Stock 25000 25000 D Stock Option (Right to Buy) 1.14 2020-03-04 4 M 0 10000 0 D 2023-09-12 Common Stock 10000 55187 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.88 to $84.77. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.91 to $85.43. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.94 to $86.73. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.98 to $87.95. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.02 to $88.80. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.04 to $89.12. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of July 31, 2019 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. The option is fully vested and exercisable. This option grant was previously reported as having an expiration date of September 11, 2023, which has been revised herein. /s/ Richard Buchholz, as Attorney-in-Fact for Randy Ban 2020-03-06